Literature DB >> 10472777

Differential regulation of normal and tumoral breast epithelial cell growth by fibroblasts and 1,25-dihydroxyvitamin D3.

C Gache1, Y Berthois, E Cvitkovic, P M Martin, S Saez.   

Abstract

Mesenchymal-epithelial interactions are of paramount importance during normal and tumoral breast developments. We have investigated the paracrine growth regulation of normal and tumoral breast epithelial cells by fibroblasts derived from normal or pathological breast tissues. In some cases, breast cancer MCF-7 cells or normal epithelial cells in primary culture were cocultured with fibroblasts in a Transwell system allowing diffusible factor exchanges. Alternatively, conditioned medium produced by fibroblast cultures was added to epithelial cell cultures. Fibroblasts were shown to stimulate the proliferation of normal and carcinoma cells through paracrine mechanisms. However, the paracrine exchanges appeared to be different in normal versus tumoral breast epithelial cell growth regulation. Moreover, vitamin D-related compounds that have been proposed as anti-tumoral drugs were studied for their ability to affect normal and tumoral mammary epithelial cell proliferation and to interfere with the growth-regulatory activity of fibroblasts. Whereas vitamin D compounds inhibited MCF-7 cell growth, they led to a marked stimulation of the proliferation of normal mammary epithelial cells. Moreover, it was shown that the vitamin D analog EB 1089 can block the mitogenic effect of fibroblast-conditioned medium on tumoral but not normal breast epithelial cells. The differential effects of vitamin D compounds on cell proliferation provide further data in favor of the different behaviours of normal and tumoral mammary epithelial cells. The potential therapeutic use of vitamin D derivatives in the treatment of breast cancer is supported by these results but their growth-stimulatory properties on normal epithelial cells cannot be overlooked.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10472777     DOI: 10.1023/a:1006163418479

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  5 in total

1.  Human breast fibroblasts inhibit growth of the MCF10AT xenograft model of proliferative breast disease.

Authors:  Andrea Sadlonova; Shibani Mukherjee; Damon B Bowe; Sandra R Gault; Nicole A Dumas; Brian A Van Tine; Natalya Frolova; Grier P Page; Danny R Welch; Lea Novak; Andra R Frost
Journal:  Am J Pathol       Date:  2007-03       Impact factor: 4.307

2.  TRPV6 determines the effect of vitamin D3 on prostate cancer cell growth.

Authors:  V'yacheslav Lehen'kyi; Maylis Raphaël; Agathe Oulidi; Matthieu Flourakis; Sergii Khalimonchyk; Artem Kondratskyi; Dmitri V Gordienko; Brigitte Mauroy; Jean-Lois Bonnal; Roman Skryma; Natalia Prevarskaya
Journal:  PLoS One       Date:  2011-02-11       Impact factor: 3.240

3.  Breast fibroblasts modulate epithelial cell proliferation in three-dimensional in vitro co-culture.

Authors:  Andrea Sadlonova; Zdenek Novak; Martin R Johnson; Damon B Bowe; Sandra R Gault; Grier P Page; Jaideep V Thottassery; Danny R Welch; Andra R Frost
Journal:  Breast Cancer Res       Date:  2004-11-08       Impact factor: 6.466

4.  Transcriptional effects of 1,25 dihydroxyvitamin D(3) physiological and supra-physiological concentrations in breast cancer organotypic culture.

Authors:  Cintia Milani; Maria Lucia Hirata Katayama; Eduardo Carneiro de Lyra; JoEllen Welsh; Laura Tojeiro Campos; M Mitzi Brentani; Maria do Socorro Maciel; Rosimeire Aparecida Roela; Paulo Roberto del Valle; João Carlos Guedes Sampaio Góes; Suely Nonogaki; Rodrigo Esaki Tamura; Maria Aparecida Azevedo Koike Folgueira
Journal:  BMC Cancer       Date:  2013-03-15       Impact factor: 4.430

5.  Interlobular and intralobular mammary stroma: genotype may not reflect phenotype.

Authors:  J M Fleming; E L Long; E Ginsburg; D Gerscovich; P S Meltzer; B K Vonderhaar
Journal:  BMC Cell Biol       Date:  2008-08-18       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.